Announcing a new funding opportunity.

NIGMS is providing co-funding for applications that just missed the Institute's payline.

And, join us for the next installment of the UVMCC & NNE-CTR Seminar Series. March 13 at 12 pm in HSRF 400. Livestream to Maine Medical Center Research Institute.

Workshops offered by the IDeA National Resource for Quantitative Proteomics

Don't miss out on this Seminar. Check out the recording of the livestream with Maine Medical Center Research Institute.

Don't miss out on this Seminar. Check out the recording of the livestream with Maine Medical Center Research Institute.

New Guidelines for Long-Term Use of Opioids

Click here for a curated and updated list of summaries of CTR-relevant opportunities.

RNAscope is an RNA in situ detection platform. The RNAscope® Assays are based on the proprietary RNAscope® Technology, enabling RNA target expression analysis within intact cells and tissues with high sensitivity and specificity. The innovative RNAscope® Assay, with in situ hybridization technology to detect mRNA and ncRNA targets of >300bp, was launched in 2011 and marks the foundation of our product portfolio. The proprietary probe design requires an average of 20 Z pairs per target, however a minimum hybridization of 6 Z pairs can be used to obtain a signal. With over 1,400 publications in peer-reviewed journals, across multiple disciplines, the RNAscope® Assay represents a revolutionary advance in in situ target RNA detection. The seminar highlighted the basis of RNAscope technology and labeling protocols, including troubleshooting tips and examples of labeling with both chromogenic and fluorescent dyes.

Click on the title for a link to access article.

An innovative initiative that will use a public health approach to inform opioid prescribing policies will be launched in northern New England thanks to a new $339,000 grant to the Northern New England Clinical and Translational Research (NNE-CTR) Network from the National Institutes of Health.